

ISSN 1262-9593

& Diabetes *Metabolism*

89 REVIEWS

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
A.J. Scheen

102 Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
B. Detournay, D. Simon, P.-J. Guillausseau, D. Joly, B. Vergès, C. Attali, O. Clement, Y. Briend, and O. Delatre

113 GUIDELINES

Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
B. Vergès, A. Avignon, F. Bonnet, B. Catargi, S. Cattan, E. Cosson, G. Ducrocq, M. Elbaz, A. Friederich, P. Gourd, P. Henry, O. Lainez, A.M. Legarrin, C. Morpains, P. Mouin, B. Vergès-Petis, R. Boussel, G. Steg, and P. Valadier, Diabetes and Cardiovascular Disease study group of the Société Francophone du diabète (SFD), in collaboration with the Société française de cardiologie (SFC)

128 ORIGINAL ARTICLES

Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS)
J.J. DiGirolamo, P. Aschner, S.H. Baik, J. Chan, J.M. Chanietot, H. Ikova, and A. Ramachandran, IDMPS investigators

135 The metabolic syndrome, incidence of diabetes and mortality among the elderly: The Italian Longitudinal Study of Ageing
M. Hoque, S. Maggi, S. Zanoni, F. Limongi, S. Zamboni, and G. Crepaldi, ILSA working group

142 Adherence to breast and cervical cancer screening in Spanish women with diabetes: Associated factors and trend between 2006 and 2010
M.A. Martínez-Huedo, A. Lopez de Andres, V. Hernandez-Barrera, R. Carrasco-Garrido, D. Martínez-Hernández, and R. Jiménez-García

149 Diabetes, comorbidities and increased long-term mortality in older patients admitted for geriatric inpatient care
D. Zekry, E. Frangos, C. Graf, J.P. Michel, G. Gold, K.H. Krause, FR. Herrmann, and U.M. Vischer

156 Insulin therapy for diabetes mellitus: Treatment regimens and associated costs
B. Chahboune, A. Penfornis, M. Yarrout-Viel, O. Kusnik-Joinville, and B. Detournay

164 The Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1) scale: Predictive validity and reliability
A.S. Braziano, H. Mircescu, K. Desjardins, M.C. Dubé, S.J. Weinagel, C. Lavoie, and R. Rabasa-Lhoret

171 Structural modifications of human albumin in diabetes
A. Guerin-Dubourg, A. Catan, E. Bourdon, and R. Rondeau

179 SHORT REPORT

A novel ABCG2 mutation illustrates the variability of the diabetes phenotypes associated with a single mutation
P. Khan, C. Bellizzi-Chantelot, G. Depret, J.P. Liano, C. Paget, and M. Nicolino

ELSEVIER MASSON

Société francophone du diabète

Indexed in: BIOSIS (Biological Abstracts), CAB/ Chemical Abstracts - Current Contents Life Sciences - EMBASE/Excerpta Medica - Medline (Index Medicus) - Parat (BIOSIS/CMB) - Research Alert - Science Citation Index - SCI Search

Bi-monthly publication April 2012 Vol. 38 **2**

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



ELSEVIER
MASSON

Available online at
SciVerse ScienceDirect
 www.sciencedirect.com

Elsevier Masson France
 EM|consulte
 www.em-consulte.com/en

Diabetes
 & Metabolism

Diabetes & Metabolism 38 (2012) 128–134

Original article

Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS)

J.J. Gagliardino^{a,*}, P. Aschner^b, S.H. Baik^c, J. Chan^d, J.M. Chantelot^e,
 H. Ilkova^f, A. Ramachandran^g, IDMPS investigators

^a Center of Experimental and Applied Endocrinology, La Plata National Scientific and Technical Research Council–La Plata National University, PAHO/WHO Collaborating Centre for Diabetes, La Plata, Argentina

^b Endocrinology Unit, Javeriana University, Bogotá, Colombia

^c Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea

^d Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China

^e Department of Intercontinental Medical Affairs, Sanofi-Aventis, Paris, France

^f Department of Internal Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

^g India Diabetes Research Foundation, Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India

Received 1st December 2010; received in revised form 1st September 2011; accepted 1st September 2011

Abstract

Aim. – To evaluate the impact of diabetes education provided to patients with type 2 diabetes mellitus (T2DM) in non-controlled studies (“real-world conditions”) on quality of care, resource consumption and conditions of employment.

Methods. – This cross-sectional study and longitudinal follow-up describe the data (demographic and socioeconomic profiles, clinical characteristics, treatment of hyperglycaemia and associated cardiovascular risk factors, resource consumption) collected during the second phase (2006) of the International Diabetes Management Practices Study (IDMPS). Patients received diabetes education directly from the practice nurse, dietitian or educator, or were referred to *ad hoc* group-education programmes; all programmes emphasized healthy lifestyle changes, self-care and active participation in disease control and treatment. Educated vs non-educated T2DM patients ($n = 5692$ in each group), paired by age, gender and diabetes duration, were randomly recruited for the IDMPS by participating primary-care physicians from 27 countries in Eastern Europe, Asia, Latin America and Africa. Outcome measures included clinical (body weight, height, waist circumference, blood pressure, foot evaluation), metabolic (HbA_{1c} levels, blood lipid profile) and biochemical control measures. Treatment goals were defined according to American Diabetes Association guidelines.

Results. – T2DM patients' education significantly improved the percentage of patients achieving target values set by international guidelines. Educated patients increased their insulin use and self-care performance, had a lower rate of chronic complications and a modest increase in cost of care, and probably higher salaries and slightly better productivity.

Conclusion. – Diabetes education is an efficient tool for improving care outcomes without having a major impact on healthcare costs.

© 2011 Elsevier Masson SAS. All rights reserved.

Keywords: Diabetes; Education; Developing countries; Costs

Résumé

Éducation des diabétiques de type 2 : impact sur les soins, la consommation des ressources et les conditions de travail. Données de l'International Diabetes Management Practices Study (IDMPS).

Objectif. – Évaluer l'impact de l'éducation prodiguée aux patients atteints de diabète de type 2 à partir de l'étude observationnelle (dans les conditions réelles de suivi des patients) de la qualité des soins et de leurs coûts, exprimés en dépenses de soins et en journées de travail perdues.

* Corresponding author.

E-mail address: cenexa@speedy.com.ar (J.J. Gagliardino).

Méthodes. – Étude transversale et longitudinale ayant pour but de recueillir des données des patients concernant leur profil socioéconomique, le traitement du diabète et de ses complications et les coûts. Cette étude appartient à la seconde vague de l'International Diabetes Management Practices Study (IDMPS) (2006). Les patients ont reçu des informations relatives au diabète d'une infirmière, d'un diététicien, d'un éducateur spécialisé ou grâce à un programme d'éducation spécifique. Chaque programme mettait l'accent sur les modifications hygiéno-diététiques et la prise en charge active de la maladie et de son traitement par le patient lui-même. Les diabétiques de type 2 qui avaient reçu ou non cette éducation ($n = 592$ dans chaque groupe) étaient appariés selon l'âge, le sexe, et la durée de diabète. Les patients avaient été recrutés par randomisation par les médecins traitants de 27 pays de l'Europe de l'Est, de l'Asie, de l'Amérique Latine et d'Afrique. Les données recueillies étaient cliniques (poids, taille, périmètre adominal, pression artérielle, examen des pieds), métabolique (HbA_{1c} , profil lipidique) et biologiques. Les objectifs de traitement étaient ceux définis par les recommandations de l'American Diabetes Association.

Résultats. – L'éducation diabétique apportée aux diabétiques de type 2 augmente significativement le pourcentage de patients atteignant les objectifs de traitement définis par les recommandations internationales. Les patients qui avaient reçu une éducation diabétologique utilisaient davantage l'insuline et se prenaient mieux en charge. Ils présentaient un plus faible pourcentage de complications chroniques. Une augmentation modérée des coûts de traitement fut notée, associée probablement à des salaires plus élevés et à une productivité légèrement plus élevée.

Conclusion. – L'éducation diabétique est efficace et améliore le devenir des patients sans élévation importante des coûts de traitement.

© 2011 Elsevier Masson SAS. Tous droits réservés.

Mots clés : Diabète ; Éducation ; Pays en voie de développement ; Coût

1. Introduction

Type 2 diabetes mellitus (T2DM) affects a large percentage of the adult population worldwide, and is responsible for the use of a large part of health-service resources, mostly due to the presence of its macrovascular complications [1–3]. The disease is also associated with increased morbidity and premature death from cardiovascular disease, conditions that have a negative impact on quality of life and individual productivity [4,5].

Although such costs may still be affordable in developed countries, this is not the case in many developing countries and, in the near future, they may become unaffordable even in the developed countries. However, the evidence suggests that this scenario may be mitigated by implementing aggressive and effective preventative strategies, such as improving the quality of care [6,7]. In this context, the active participation of patients in disease control and treatment after patients' empowerment for successful self-management may play a key role in optimizing metabolic and risk factor control, and quality of life [8–11]. Although patients' education may be pivotal in encouraging and supporting patients to assume such an active responsibility [12,13], in many places, patients do not have easy access to diabetes education programmes. The traditional medical model in which patients are merely passive recipients of care only partly explains the situation [14].

Educational programmes developed worldwide [15–18] have shown that a firm theoretical basis and the use of cognitive reframing are associated with improved outcomes [19,20]. In this regard, the Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) study recently reported that a structured group-education programme for patients with newly diagnosed T2DM led to greater improvements in weight loss and smoking cessation, as well as more positive beliefs about illness, with no differences in levels of glycated haemoglobin (HbA_{1c}) up to 12 months after diagnosis [21]. However, many people still claim that the evidence available for the effectiveness of any educational approach in patients with T2DM is scanty [10,22,23]. They also argue that most of the published data come from controlled research studies

implemented in comparatively small populations or patient cohorts, and that there is little or no data for T2DM patients' education outcomes in "real-world conditions" worldwide.

In response to this criticism, we have evaluated the impact of diabetes education in non-controlled studies on quality of care, resource consumption and employment conditions. The data obtained revealed significant improvement in care indicators in a large population of such educated patients with T2DM recruited from different countries in Africa, Asia, Eastern Europe, the Middle East and Latin America, with care-indicator values close to the treatment goals recommended in the European Association for the Study of Diabetes/American Diabetes Association (EASD/ADA) guidelines [24].

2. Methods

2.1. Participants

Participants in the International Diabetes Management Practices Study (IDMPS) were recruited from 27 countries in Eastern Europe, Asia, Latin America and Africa during November and December of 2006 (Table 1). Physicians were requested to enroll the first ten patients with T2DM and the first five patients with type 1 diabetes (T1DM) visiting their offices during the 2-week recruitment period. Details of the criteria used for patients' and physicians' selection have been reported elsewhere [25]. For the present study, data from 11,384 patients with T2DM were

Table 1
Characteristics of the paired sample of patients.

	Received diabetes education		P value
	No	Yes	
Number of participants	5692	5692	
Age (years; mean \pm SD)	57.7 \pm 11.1	57.7 \pm 11.1	0.947 ^a
Gender (female)	53.1%	53.1%	1.000 ^b
Time since diagnosis (years)	8.0 \pm 7.0	8.1 \pm 7.0	0.810 ^a

^a Wilcoxon test.

^b Chi-square test.

used; within this population, those patients who had received diabetes education, albeit with different teaching characteristics and degrees of intensity (“educated” patients), and those who had not (“non-educated” patients) were identified. Thereafter, the patients in both groups were paired by age, gender and diabetes duration, with 5692 patients finally allocated to each group.

2.2. Procedures

The IDMPS is an ongoing 5-year study with five phases. Each phase consists of a cross-sectional period lasting 2 weeks in each study centre, followed by a 9-month longitudinal follow-up period [25]. The present study is based on the data recorded during the cross-sectional study of the second phase (2006); thus, the practices included here represent the wide spectrum of routine care currently available in the participating countries.

During the cross-sectional period, physicians collected information on the patients’ demographic and socioeconomic profiles, relevant medical history (chronic complications, associated cardiovascular risk factors and co-morbidity factors), previous and current treatments for hyperglycaemia and its associated cardiovascular risk factors, disease-related education, and employment conditions and performance.

2.3. Outcome measures

Clinical data (body weight, height, waist circumference, blood pressure, foot evaluation) were collected at practice visits. Metabolic control measures included HbA_{1c} levels and blood lipid profiles [total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides]. Blood samples were collected and assayed locally, applying the same methodology in all participating countries to maximize data robustness and to allow regional comparisons.

Treatment goals were defined according to ADA guidelines [HbA_{1c} < 7%, blood pressure (BP) < 130/80 mmHg, LDL-C < 100 mg/dL] [24].

2.4. Educational strategies

The participating centres offered various diabetes-education strategies: face-to-face consultation with a practice nurse, dietitian or educator (67%); referral to an *ad hoc* structured group-education programme with different degrees of complexity and numbers of interactive sessions (22%); or both (11%). All strategies placed strong emphasis on healthy lifestyle changes (meal-planning and regular bouts of physical activity), self-care and active patient participation in disease control and treatment. Educational contents included general concepts of T2DM, effect of obesity on insulin demand and benefits of weight loss, performance of self-monitoring of blood glucose (SMBG) and clinical self-monitoring, physiological changes in serum glucose levels and symptoms of hypo-/hyperglycaemia. The minimum frequency of clinical control and laboratory tests necessary for good diabetes care was also included.

The IDMPS study protocol was approved by the appropriate regulatory and ethics committees in all of the participating countries and centres. Accordingly, all participants provided written informed consent before entering the study. Implementation was developed under the guidance of a steering committee that also proposed the statistical analyses, and reviewed and validated the registry data [25].

The study was coordinated by Sanofi-Aventis Intercontinental (Sanofi-Aventis Group). In each participating country, the study was monitored by Sanofi-Aventis staff, who assisted the local coordinators and investigators in collecting data through a study case-report form.

2.5. Statistical analysis

Data were analyzed using Wilcoxon’s and Chi-square tests for continuous and categorical variables, respectively.

3. Results

There were no significant differences between the educated and non-educated groups in terms of age, gender and diabetes duration, due to the pairing process used to select the patients included in the two arms of the study (Table 1). However, the percentage of illiterate individuals was significantly higher among the educated vs non-educated patients (9.9% vs 8.3%, respectively) and, in the latter group, the percentage of patients with higher/university-level education was higher (27.8% vs 25.1% in the educated group). No significant differences were recorded between groups as regards current or previous smoking habits.

Mean body mass index (BMI) and waist circumference values were significantly lower among educated patients (Table 2). In addition, the percentage of those with BMIs within the normal range was also significantly higher in this group, whereas the opposite situation was observed in patients who were overweight/obese.

No significant differences were recorded between groups in either systolic blood pressure (SBP) absolute values or percentage of patients with values within treatment goals (< 130 mmHg); conversely, the mean value and percentage of patients with normal diastolic BP (DBP) values were significantly lower and higher, respectively, in the educated group (Table 2). Similarly, the percentage of people with SBP and DBP at target values was significantly higher in the educated group.

In addition, performance of HbA_{1c} control was significantly higher among the educated patients, who had significantly lower mean and median values, and a higher percentage of patients with values less than 7% (Table 2).

Serum lipid profiles (total cholesterol, LDL-C and triglycerides) showed significantly lower mean values in the educated arm. The percentage of patients with serum LDL-C and triglyceride levels within the normal range was also significantly higher in this group. On the other hand, comparable HDL-C levels were measured in both groups of patients.

As for chronic complications, no significant differences between groups were recorded in the percentage of those with

Table 2
Patients' clinical and metabolic indicators and chronic complications.

	Received diabetes education		P value
	No	Yes	
Number of participants	5692	5692	
BMI (kg/m ²)	28.5 ± 5.2	28.2 ± 5.2	< 0.001 ^a
≤ 18.5	0.7%	0.8%	
> 18.5–25	24.4%	28.3%	
> 25–30	41.8%	39.5%	
> 30–35	22.4%	21.4%	
> 35	10.8%	9.9%	
Waist circumference (cm)	97.7 ± 13.6	96.3 ± 13.8	< 0.001 ^a
SBP	133 ± 18	133 ± 18	NS
DBP	80.1 ± 10.2	79.5 ± 10.4	< 0.001 ^a
< 80 mmHg	32.3%	36.5%	< 0.001 ^b
SBP < 130 mmHg and DBP < 80 mmHg	20.8%	23.7%	< 0.001 ^b
HbA _{1c} measurements in the past year:			
0	2.9%	2.6%	
1	37.4%	33.5%	
2	29.2%	27.4%	
3	17.1%	18.7%	< 0.001 ^a
4	10.3%	13.5%	
Mean ± SD	2.1 ± 1.4	2.24 ± 1.41	
Value of last HbA _{1c} measurement	7.9 ± 1.9	7.8 ± 1.9	0.009 ^a
Median	8	7	
Q1–Q3	7–9	7–9	0.009 ^a
HbA _{1c} < 7%	35.8%	38.1%	0.032 ^b
HbA _{1c} > 8%	37.3%	34.6%	0.028 ^b
Total cholesterol (mg/dL)	198.3 ± 53.4	194.4 ± 54.3	< 0.001 ^a
LDL-C (mg/dL)	134.9 ± 145.1	125.9 ± 125.7	< 0.001 ^a
< 100 mg/dL	33.0%	39.5%	< 0.001 ^b
Triglycerides (mg/dL)	184.7 ± 150.7	179.6 ± 159.2	< 0.001 ^a
< 150 mg/dL	49.0%	52.7%	< 0.001 ^b
Foot ulcer	3.5%	2.4%	0.026 ^b
Patients screened and with complications within the last 12 months			
Peripheral vascular disease	5.7%	4.2%	0.002 ^b
Patients screened and with complications within the last 12 months			

Data are presented as means ± SD unless otherwise stated; BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; LDL-C: low-density lipoprotein cholesterol.

^a Differences between groups were measured using Wilcoxon tests for continuous and categorical variables, respectively.

^b Differences between groups were measured using Chi-square tests for continuous and categorical variables, respectively.

angina, acute myocardial infarction/acute coronary syndrome, heart failure or stroke. However, significantly lower percentages of proteinuria (13.3% vs 16.7%; $P < 0.001$), foot ulcer (2.4% vs 3.5%; $P < 0.026$) and peripheral vascular disease (4.2% vs 5.7%; $P < 0.002$) were recorded in the educated group.

Resource consumption is summarized in Table 3. In the group of educated patients, the annual number of visits to specialists (21% higher; $P < 0.001$), the percentage of those treated with insulin (40% higher; $P < 0.001$), and the average performance of fasting (3% higher; $P < 0.001$) and postprandial (52% higher; $P < 0.001$) SMBG were all significantly increased. Indeed, differences in SMBG performance were even larger when the highest monthly frequencies were considered.

As regards employment and performance at work, the percentage of people with full-time jobs was higher in the educated than in the non-educated group (35.0 vs 34.2%; $P > 0.002$ by Chi-square test). Also, although not significantly different, annual absenteeism figures were 15% higher among non-educated than educated patients (6.24 ± 31.45 vs 5.41 ± 23.91 days/year, respectively; $P < 0.12$ by Chi-square test).

4. Discussion

Our present data show that most of the clinical and biochemical indicators measured in T2DM patients receiving different kinds of diabetes education decreased significantly.

Table 3
Patients' resource use, diabetes treatment and self-monitoring of blood glucose (SMBG).

	Received diabetes education		P value
	No	Yes	
Number of participants	5692	5692	
Visits to specialist	5.91 ± 5.49	7.18 ± 7.00	<0.001 ^a
Annual resource use per patient			
Visits to diabetes educator	0.00 ± 0.00	2.91 ± 4.32	<0.001 ^a
Annual resource use per patient			
Type of diabetes treatment			<0.001 ^b
OGLD treatment alone ^c	70.3%	61.6%	
Insulin treatment (with/without OGLD) ^c	25.0%	34.9%	
Diet and exercise alone	4.7%	3.5%	
SMBG (FBG or PPG; yes)	39.6%	51.4%	
Frequency of self-monitoring of FBG/month	12.06 ± 12.65	12.41 ± 12.64	0.013 ^a
Frequency/month (classes)			
1–5 times/month	41.5%	36.8%	
6–10 times/month	22.7%	25.3%	
11–15 times/month	13.0%	13.7%	0.011 ^b
16–30 times/month	19.6%	21.5%	
> 30 times a month	3.2%	2.6%	
Does the patient self-monitor PPG using glucometer?	24.7%	37.5%	
Yes			
Frequency of self-monitoring of PPG/month	8.99 ± 10.60	9.76 ± 10.98	<0.001 ^a

Data are presented as means ± SD unless otherwise stated; OGLD: oral glucose-lowering drug; FBG: fasting blood glucose; PPG: postprandial glucose.

^a Differences between groups were measured by Wilcoxon tests for continuous and categorical variables, respectively.

^b Differences between groups were measured by Chi-square tests for continuous and categorical variables, respectively.

^c Associated with diet and exercise prescription.

The frequency of HbA_{1c} measurements and the percentage of patients with HbA_{1c} levels at target values, according to international guidelines, were significantly higher in the educated group, with a median concentration at 1 point below target. According to the United Kingdom Prospective Diabetes Study (UKPDS) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) Trial results, such a decrease in HbA_{1c} values would, in turn, reduce the risk of developing microangiopathic complications by about 25% [26,27].

Similarly, markers of the other cardiovascular risk factors measured—namely, BMI (obesity), and BP and lipid profiles—were also lower in the educated group. Although of small magnitude, these changes were statistically significant and within the range reported in controlled diabetes-education studies [15,18–20,28]. Based on data reported in the literature, such lower values can decrease the risk of cardiovascular disease:

- Albu et al. [29] reported that, in cross-sectional analyses, both BMI and waist circumference were independently associated with increased atherothrombotic risk in centrally obese cohorts, such as the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) patients, with T2DM and coronary artery disease;

- a reduction in BP decreases microvascular and macrovascular events [30];
- both the Helsinki Heart Study and the Scandinavian Simvastatin Survival Study (4S) [31,32] showed that high HDL-C and low LDL-C levels effectively contribute to the prevention of coronary heart disease;
- the Steno-2 trial, which simultaneously lowered HbA_{1c}, BP and lipids in patients with T2DM, demonstrated relevant long-term reductions in cardiovascular disease and mortality [33].

Regarding the type of treatment, our records showed a greater percentage of insulin use as well as a higher percentage and frequency of SMBG in the educated patients. Also, despite the greater use of insulin, it is worth mentioning that their BMI was lower than in the non-educated group, thereby indicating that hormone administration did not induce body weight increases as it normally would. Taken altogether, these differences indicate greater active involvement of educated patients in the control and treatment of their disease, as well as better compliance with prescribed treatments (including meal-planning) and improved performance of self-care.

As previously shown [26,30,33–35] and, thus, consequently expected, such better profiles of control indicators were accompanied by significantly lower rates of foot ulcers and peripheral

vascular disease. Evidently, the above-mentioned characteristics also impacted favourably on the chances of educated patients to earn higher salaries: a significantly larger percentage with full-time jobs, and a slightly – although not significantly – lower rate of absenteeism from work were recorded in this group. These data agree with the previous results showing how poor disease control and the development of chronic complications had negative impacts on workers' productivity [5].

On the other hand, resource consumption was significantly higher in educated patients; the annual number of visits to specialists was 21% higher, as was insulin use (40%), and performance of fasting (30%) and postprandial (9%) SMBG. However, the increased cost of care represented by such consumption was not estimated in monetary values in our study. As the educated group also had lower rates of chronic complications – the main engine driving the costs of care up [2,3,36,4] – we assume that this would soon be of benefit to healthcare providers due to lower costs of care for these patients in the near future. This beneficial situation could, in addition, affect the families of educated patients, as they are more likely to earn higher incomes (full-time jobs) and spend less out-of-pocket money for disease treatment. It should be borne in mind, however, that the development and progression of chronic complications are also affected by other factors, such as general education and socioeconomic levels.

Quality of life was not assessed in the IDMPS; however, based on other studies reporting that education improves quality of life [16,21,37], similar results would be expected among our educated patients.

The limitations and difficulties of carrying out pragmatic interventional trials in a primary-care setting are well recognized [38,39]; consequently, our conclusions are subject to a number of constraints. One concerns the nature of the present study, which was observational rather than a randomized controlled trial. The latter trials are considered superior to observational studies because they eliminate selection bias and reduce confounding factors [40]. However, from the point of view of generalizability, data from observational studies are usually applicable to much wider populations and are often even population-based [41]. Nevertheless, in the present case, such generalizability is limited by the fact that the data recorded in different countries are not necessarily representative, one reason why the findings need to be applied with caution.

Other limitations are the heterogeneity of the educational procedures used, the differences in accessibility to education and care, the differences in healthcare settings and the different cultural predispositions in each participating country. In fact, our study included a wide variety of methodologies and interventional durations compared with the standardized educational programmes. This could represent a serious challenge, as a positive effect on metabolic control strongly correlates with patients' motivation, number of training sessions, and quality of the relationship between the patient and caregiver/instructor [42]. However, it could be argued that, even though our patients did not receive identical multidimensional therapeutic education, the education that was received was sufficient to attain HbA_{1c} levels comparable to those recorded in well-controlled studies [42]. For this reason, the differences found in our present study

might have been of even greater magnitude if standardized procedures had been implemented. Also, given our sample size (the largest so far reported) and the paired comparison performed, all of the above-mentioned limitations might be mitigated, if not removed completely, thus lending additional support to the favourable impact of patients' education on diabetes care outcomes.

5. Conclusion

In brief, the IDMPS data demonstrate that, in T2DM patients, diabetes-related education involving different characteristics and degrees of intensity, and implemented worldwide in a large population at the primary-care level, significantly increased the percentages of patients achieving target values as set by the international guidelines. Among educated patients, the rate of chronic complications was lower while insulin use and self-care performance were higher, resulting in a relatively modest increase in costs of care in this group. These results should help healthcare providers and policy makers to arrive at the decision to include diabetes education as an efficient and routine therapeutic tool within the strategies used to control and treat patients with diabetes.

Disclosure of interest

The IDMPS is an epidemiological survey entirely funded by Sanofi-Aventis. J.-M. C. is an employee of Sanofi-Aventis, a sponsor of the IDMPS. All the other authors are members of the IDMPS steering committee, and have received honoraria and traveling sponsorships related to the IDMPS.

Acknowledgments

We thank the staffs of all physicians' offices for their excellent efforts and all our colleagues for the various forms of assistance that led to the successful completion of the second phase of this global study. Participants had full access to all the data in the study and take responsibility for the accuracy of the data analysis. The authors are also grateful to A. Di Maggio for assistance in editing the manuscript.

References

- [1] International Diabetes Federation. IDF diabetes atlas – prevalence estimates of diabetes mellitus; 2007; www.eatlas.idf.org.
- [2] Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. *Diabetes Care* 1997;20:1396–402.
- [3] Rubin R, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. *J Clin Endocrinol Metab* 1994;78(809A):809F.
- [4] American Diabetes Association. Economic costs of diabetes in the US in 2007. *Diabetes Care* 2008;31:596–615.
- [5] Bolin K, Gip C, Mörk AC, Lindgren B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005 – a register-based approach. *Diabet Med* 2009;26:928–34.
- [6] UKPDS, CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and

- serum cholesterol level reduction for type 2 diabetes. *JAMA* 2002;287:2542–51.
- [7] Cleveringa FG, Welsing PM, van den Donk M, Gorter KJ, Niessen LW, Rutten GE, et al. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. *Diabetes Care* 2010;33:258–63.
- [8] Davies MJ, Carey ME, Dallosso HM, Heller S, Khunti K, Skinner TC. Effects of a structured education programme on illness beliefs, QoL and physical activity in individuals newly diagnosed with type 2 diabetes: the DESMOND pilot study. *Diabetologia* 2006;49(Suppl 1):S35.
- [9] Skinner T, Cradock S, Arundel F, Graham W. Four theories and a philosophy: self-management education for individuals newly diagnosed with type 2 diabetes. *Diabetes Spectr* 2003;16:75–80.
- [10] Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. *Diabetes Care* 2002;25:1159–71.
- [11] Lorig K. Partnerships between expert patients and physicians. *Lancet* 2002;359:814–5.
- [12] National Institute for Clinical Excellence. Guidance on the use of patient-education models for diabetes (Technology Appraisal 60). London: NICE; 2003.
- [13] Rutten G. Diabetes patient education: time for a new era. *Diabet Med* 2005;22:671–3.
- [14] van Dam HA, van der Horst F, van den Borne B, Ryckman R, Crebolder H. Provider–patient interaction in diabetes care: effects on patient self-care and outcomes: a systematic review. *Patient Educ Couns*; 2003.
- [15] Kronsbein P, Jorgens V, Muhlhauser I, Scholz V, Venhaus A, Berger M. Evaluation of a structured treatment and teaching programme on noninsulin-dependent diabetes. *Lancet* 1988;2:1407–11.
- [16] Trento M, Passera P, Borgo E, Tomalino M, Bajardi M, Cavallo F, et al. A 5-year randomized controlled study of learning, problem solving ability, and quality of life modifications in people with type 2 diabetes managed by group care. *Diabetes Care* 2004;27:670–5.
- [17] Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, et al. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. *Diabetes Care* 2001;24:695–700.
- [18] Gagliardino JJ, Etchegoyen G, The PEDNID-LA Research Group. A model educational program for people with type 2 diabetes. A cooperative Latin American implementation study (PEDNID-LA). *Diabetes Care* 2001;24:1001–7.
- [19] Glasgow RE, Hampson SE, Strycker LA, Ruggiero L. Personal-model beliefs and social-environmental barriers related to diabetes selfmanagement. *Diabetes Care* 1997;20:556–61.
- [20] Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA. Diabetes patient counseling: a meta-analysis and meta-regression. *Patient Educ Couns* 2005;52:97–105.
- [21] Davies MJ, Heller S, Skinner TC, Cradock S, Dallosso HM, Daly H, et al. Effectiveness of the diabetes education and self-management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. *BMJ* 2008;336:491–5.
- [22] Norris SL, Engelgau MM, Narayan KM. Effectiveness of self management training in type 2 diabetes: a systematic review of randomized controlled trials. *Diabetes Care* 2001;24:561–87.
- [23] Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2005;CD003417.
- [24] Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 2006;49:1711–21.
- [25] Chan JCM, Gagliardino JJ, Baik SH, Chantelot J-M, Ferreira SRG, Hancu N, et al. Multifaceted determinants for achieving glycemic control the International Diabetes Management Practice Study (IDMPS). *Diabetes Care* 2009;32:227–33.
- [26] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837–53.
- [27] Heller SR, The ADVANCE Collaborative Group. A summary of the ADVANCE Trial. *Diabetes Care* 2009;32(Suppl 2):S357–61.
- [28] Berger M, Jörgens V, Flatten G. Health care for persons with non-insulin-dependent diabetes mellitus. The German experience. *Ann Intern Med* 1996;124:153–5 [Review; 19].
- [29] Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, et al. Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Obesity* 2010;18:1046–54.
- [30] The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2008;358:2560–72.
- [31] Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA* 1998;260:641–51.
- [32] Pyorala K, Perdersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;20:614–20.
- [33] Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358:580–91.
- [34] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- [35] Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet* 2009;373:1765–72.
- [36] Martin S, Schramm W, Schneider B, Neeser K, Weber C, Ludwig V, et al. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). *Exp Clin Endocrinol Diabetes* 2007;115:495–501.
- [37] Ménard J, Payette H, Dubuc N, Baillargeon JP, Maheux P, Ardilouze JL. Quality of life in type 2 diabetes patients under intensive multitherapy. *Diabetes Metab* 2007;33:54–60.
- [38] Moher M, Yudkin P, Wright L, Turner R, Fuller A, Schofield T, et al. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. *BMJ* 2001;322:1338–42.
- [39] Wilson S, Delaney BC, Roalfe A, Roberts L, Redman V, Wearn AM, et al. Randomised controlled trials in primary care: case study. *BMJ* 2000;321:24–7.
- [40] Scifres CM, Iams JD, Klebanoff M, Macones GA. Metaanalysis vs large clinical trials: which should guide our management? *Am J Obstet Gynecol* 2009;200(5):484.e1–5.
- [41] Hannan EL. Randomized clinical trials and observational studies. Guidelines for assessing respective strengths and limitations. *J Am Coll Cardiol Intv* 2008;1:211–7.
- [42] Lager G, Golay A. A 5 dimension therapeutic patient education for type 1 diabetic patients. *Educ Ther Patient/Ther Patient Educ* 2010;2:S117–24.